Ophthalmic Goods Merchant Wholesalers (U.S., NAICS 423460)

1. Overview

This is the middle of the eyewear supply chain: the businesses that buy eyeglass lenses, frames, sunglasses, contact lenses, and optometric equipment in bulk and resell them to the eye doctors, opticians, and retailers who put them on customers' faces. A "merchant wholesaler" is a firm that takes legal title to goods, holds inventory, and earns a spread between what it pays a manufacturer and what it charges a professional buyer — plus fees for services layered on top (lab work, next-day fulfillment, prescription handling, practice software).[4]

Why an investor should care: eyewear is a large, resilient, replacement-driven consumer-health market — roughly 42% of Americans are myopic (nearsighted), and the aging population keeps pulling more people into reading glasses and progressives.[6] The Vision Council estimates about 250 million U.S. adults, or 94%, regularly used some form of eyewear in 2025 — prescription glasses, readers, or sunglasses — underscoring why the category is less discretionary than ordinary fashion accessories.[24] Distribution is the quiet toll booth in the middle. But it is also under pressure: the biggest manufacturers increasingly own their own distribution and retail, which squeezes the independent middleman.

Optical laboratories blur the boundary between wholesaler and manufacturer. They purchase lens blanks and coatings but then surface, tint, coat, and edge lenses to a patient-specific prescription. National Vision's description of its laboratory network illustrates the workflow: centralized facilities receive electronic orders, grind and coat lenses, edge them to a selected frame, and route finished jobs back to stores — activity that can sit inside a retailer, manufacturer, or wholesaler, so company-level accounts rarely map cleanly to one NAICS code.[25]

Ways in differ sharply by investor type. There is no U.S.-listed pure-play ophthalmic wholesaler to buy. Public-market exposure comes through the vertically integrated manufacturer-distributors (mostly foreign-domiciled) that dominate supply. The classic independent distributors — the firms that actually sit squarely in NAICS 423460 — are privately held, mostly owned by private-equity firms. Details are in sections 4 and 10.

2. What it is and how it's structured

NAICS 423460 covers merchant wholesale distribution of "professional equipment, instruments, and goods sold, prescribed, or used by ophthalmologists, optometrists, and opticians": ophthalmic frames, ophthalmic lenses and lens blanks, sunglasses, contact lenses, magnifiers, binoculars, and optometric equipment and supplies.[4]

What it excludes (important for sizing the industry):

• Manufacturing of lenses, frames, and contact lenses — that is NAICS 339115 (Ophthalmic Goods Manufacturing). Much of the real distribution volume in this industry actually flows through manufacturers' own sales and distribution arms, which are counted under manufacturing, not here (see the undercount note in section 3).
• Retail — optical stores and eyewear e-tailers sit in retail codes (e.g., 456130 Optical Goods Stores), not wholesale.
• Medical/dental/hospital equipment wholesaling (NAICS 423450) and photographic/camera wholesaling — cameras are specifically excluded.[4]

Ownership mix: a barbell. On one end, a small number of very large, often vertically integrated distributors (some owned by manufacturers, some by private equity); on the other, a long tail of small independent and family-owned distributors and labs. Federal data reports 859 firms operating 999 establishments — so most firms run a single location.[1][2]

3. How big it is

Ground-truth federal statistics for NAICS 423460:

That works out to average annual pay near $77,000 per employee and average revenue near $15 million per firm — figures consistent with a distribution business (high sales per head, modest headcount, a few large players lifting the averages).[1][2]

A separate Census gross-margin profile for merchant wholesalers (excluding manufacturers' sales branches and offices) reports $12.0 billion in own-account sales, with purchases of $7.1 billion, cost of goods sold of $7.0 billion, and year-end inventory of $1.6 billion.[26] That profile yields a gross margin of 42% and Census-defined "gross profit" (gross margin minus operating expenses) of $2.2 billion, or about 18% of sales — survey constructs that precede interest, taxes, and some non-operating items rather than GAAP net income.[26]

Concentration. The four largest firms take about 37% of revenue, the top eight about 51%, the top 20 about 70%, and the top 50 about 82% — leaving a real but shrinking long tail.[2] The Herfindahl-Hirschman Index (HHI, a standard concentration gauge where under 1,500 is "unconcentrated") is just 457.5, which technically reads as fragmented.[2] The tension between a low HHI and high top-50 share reflects the barbell structure: no single firm dominates the counted wholesaler population, yet a handful of players set the tone.

The undercount caveat — read this. Federal wholesale statistics materially understate the economics of ophthalmic distribution. The dominant flows of lenses, frames, and contact lenses move through vertically integrated giants — EssilorLuxottica, Alcon, CooperVision, Bausch + Lomb, Johnson & Johnson Vision — whose distribution activity is booked under manufacturing, not merchant wholesaling. Private industry trackers that draw the boundary around "glasses and contacts wholesaling" more broadly put the number higher: IBISWorld estimated roughly $16.5 billion in 2025.[5] For scale, the total U.S. eyewear market (all channels, retail value) was about $40.8 billion in 2025.[6] The Vision Council, using a broader "optical market" definition that includes eye exams, valued the entire category at $69.5 billion in 2025 — an end-market measure, not NAICS 423460 wholesale revenue, but useful context on overall scale.[24] So the $12.7 billion federal figure captures the independent-distributor slice, not the whole distribution economy.

4. The investable universe

There is no listed U.S. pure-play ophthalmic wholesaler. Investors get exposure two ways: (a) the large, mostly non-U.S. manufacturer-distributors whose "professional/wholesale" segments supply this channel, and (b) privately held distributors, most owned by private equity.

Public companies with wholesale/distribution exposure (tickers and figures for reference only):

Retail-adjacent public names (not wholesalers, but part of the same demand chain): National Vision (Nasdaq: EYE) and Warby Parker (NYSE: WRBY).

Major private / PE-owned distributors — the firms actually at the center of NAICS 423460:

• ABB Optical Group — the largest independent U.S. contact-lens distributor; distributes over 700 million lenses a year to ~23,000 independent eye-care professionals, roughly 75% of the independents that use a distributor, and also runs a large independent eyeglass-lab network. Owned by private-equity firm New Mountain Capital.[15][16]
• Walman — historically the largest independent U.S. optical-lab group (~35 lens-surfacing/finishing labs and distribution hubs for instruments and frames); acquired by EssilorLuxottica in 2022.[14]
• 1-800 Contacts — the largest U.S. contact-lens seller (direct-to-consumer, a distribution powerhouse rather than a classic wholesaler); owned by KKR since a ~$3 billion-plus 2020 buyout.[17]
• VSP Vision / Marchon — VSP, a large not-for-profit vision insurer, owns the Marchon frames distribution business (serving 80,000+ accounts in over 100 countries) and, since 2022, the PECAA buying group.[18][33] VSP completed its acquisition of Marcolin in December 2025, further consolidating frame distribution.[34]
• Buying groups that aggregate purchasing power for independents — e.g., Vision Source (owned by EssilorLuxottica since 2015) and PECAA (VSP).[19][18]

5. How the money works

Owners in this industry make money the way all distributors do — on gross margin (buy low in bulk, sell at a markup) minus the cost of warehousing, logistics, sales force, and credit — then stack higher-margin services on top. Census data show a 42% gross margin on own-account sales and operating expenses around 24% of sales, leaving the remainder for interest, taxes, and profit.[26] The metrics that matter:

• Gross margin and product mix. Commodity contact-lens boxes carry thin margins; value-added lab work (surfacing, anti-reflective coatings, edging), private-label product, and specialty lenses carry more. Premium progressive lenses, high-index materials, and photochromic treatments generally improve gross profit dollars. Designer frames often carry royalties and minimum commitments, while fashion changes create markdown and obsolescence risk.
• Inventory turns and cash conversion. Distribution lives and dies on working capital — how fast inventory turns and how quickly receivables (often from small practices the distributor finances) convert to cash.
• Fill rate and speed. Same-day/next-day fulfillment and drop-ship-to-patient are the core competitive promise; a missed shipment loses a practice's loyalty.
• Customer retention and volume. Revenue is recurring — contact lenses are consumables and prescriptions renew — so retention compounds. ABB, for instance, cites historical retention above 95%.[16] High volume also earns manufacturer rebates, the difference between a profitable and unprofitable distributor.
• Services and data as the margin engine. The durable profit increasingly comes from what surrounds the box: prescription verification and compliance handling, financing, practice-management and analytics software, managed-vision-care claims processing, and lab services. These lock in customers and lift blended margins above what pure product resale earns.

Vertical integration changes bargaining power. National Vision notes that a limited number of vendors supply most of its lenses and contacts, and its EssilorLuxottica agreement gives that supplier the exclusive right to provide certain lenses through May 2028.[25] The structural threat to this model: when a manufacturer sells direct to the practice (or owns the retailer), the independent distributor's spread disappears. Margin defense is the whole game.

6. What drives demand

Demand is largely non-discretionary at the core, with a discretionary premium layer on top:

• Vision-correction prevalence and demographics. About 42% of Americans are myopic, and the 65-and-over population — the heaviest users of progressive and multifocal lenses as presbyopia (age-related loss of near focus) sets in — is projected to exceed 84 million by 2060.[6] The National Eye Institute projects that U.S. visual impairment or blindness could exceed 8 million cases by 2050, with another 16.4 million having difficulty seeing from correctable refractive errors.[35] This is a steady, multi-decade tailwind.
• The replacement cycle. Contact lenses are consumables; the shift toward daily disposables multiplies unit volume. Glasses prescriptions renew on roughly one- to two-year cycles.
• Screens and digital eye strain. Heavy screen use accelerates myopia in the young and drives demand for blue-light and specialty lenses; a majority of U.S. adults report digital-eye-strain symptoms.[6] BLS projects optometrist employment to grow 8% from 2024 to 2034, citing aging, increasing myopia, digital eye strain, and diabetes as drivers.[36]
• New categories. Myopia management for children (specialty soft lenses and orthokeratology) is a growing, higher-value segment. Smart eyewear — AI-enabled glasses — is another emerging category that can increase average selling prices and replacement frequency, though it introduces faster obsolescence and reliance on technology partners.[28]
• Vision insurance. Coverage through plans like VSP and EyeMed increases purchase frequency and steers where product flows. There is insurance seasonality: National Vision reports that its first two fiscal quarters normally represent a higher portion of sales, partly because health and vision benefits reset early in the year.[25]
• Fashion and premiumization. Frames and sunglasses carry a discretionary, brand-driven layer that adds cyclicality — the premium upgrades soften in downturns even as the medical core holds. The Vision Council found that the U.S. optical market increased in dollar value in 2025 even though unit volume and eye exams declined, meaning price and mix carried growth.[24]
• Channel mix. E-commerce is more substitution of channel than destruction of product demand. A late-2024 survey found 86% of recent eyeglass purchases occurred in person, while 35% of contact-lens purchases occurred online — prescription complexity and fitting preserve the practice-based channel for spectacles; standardized replenishment makes contacts easier to move online.[37]

7. Regulation

• Contact lenses are FDA-regulated medical devices (Class II/III), as are lens-care solutions. Distributors handling them face federal device requirements; this is not general merchandise.[38]
• Spectacle lenses, frames, and sunglasses are also FDA-regulated — classified as medical devices generally exempt from premarket 510(k) notification, but U.S. manufacturers and initial importers must register, manufacturers must list devices, quality-system rules apply, and spectacle and sunglass lenses must meet the impact-resistance requirement in 21 CFR 801.410. Noncompliant imports may be detained.[39]
• FTC Contact Lens Rule (16 CFR Part 315), implementing the Fairness to Contact Lens Consumers Act (effective 2004, amended 2020). It forces prescribers to release a patient's prescription automatically and lets patients buy from any seller; sellers may dispense only against a verified prescription.[8][9][10] This rule is why mail-order and online contact-lens distribution exists at scale — it pried the prescription loose from the prescriber — and its verification mechanics shape every seller's compliance operation.
• FTC Eyeglass Rule (updated 2024) strengthens automatic prescription release for eyeglasses and, for financially interested prescribers, generally requires confirmation records to be retained for at least three years. Easier prescription portability supports online and independent sellers but raises compliance burdens at integrated practices.[40]
• State optometry/optician licensing governs who may prescribe and dispense; wholesalers sell to licensed professionals, not consumers.
• Antitrust. Vertical integration in this industry draws scrutiny. The 2018 Essilor–Luxottica merger — combining the largest lens maker with the largest frame/retail company — was cleared unconditionally by the FTC and EU regulators, though critics argued it concentrated the supply chain.[11][12] EssilorLuxottica's later $8.5 billion GrandVision acquisition required divesting 351 stores in Europe.[13] The FTC has separately litigated antitrust issues around online contact-lens selling, and manufacturers' "unilateral pricing policies" on lenses drew private antitrust litigation.
• Trade/tariffs. Most frames are imported (notably Italy and China), so import duties feed directly into distributor costs. The Vision Council flagged severe tariff exposure for Chinese-origin optical goods during 2025; because rates have since changed, specific percentages are not reliable, but the underlying exposure to abrupt duty increases remains.[41] National Vision notes that most of its frames are sourced or manufactured in China and that further tariffs or trade restrictions could require price increases or alternative suppliers.[25]

8. Competitive dynamics and consolidation

The defining feature is vertical integration by a few giants. EssilorLuxottica alone spans lens and frame manufacturing, wholesale distribution (Professional Solutions), major retail chains (LensCrafters, Sunglass Hut, Pearle Vision, Target Optical), the dominant frame brands (Ray-Ban, Oakley) and licensed designer eyewear, plus optometrist networks (Vision Source).[23][20] That reach lets it supply — and compete with — the very independents an ophthalmic wholesaler serves.

The distribution layer itself is consolidating:

• ABB Optical rolled up rival contact-lens distributors (Con-Cise) to build the leading independent platform, backed by New Mountain Capital.[15]
• EssilorLuxottica bought Walman (labs) and Vision Source (buying group).[14][19]
• VSP bought the PECAA buying group and completed its acquisition of Marcolin in December 2025.[18][34]
• KKR took 1-800 Contacts private.[17]

The strategic fault line: independent distributors (led by ABB) win by being the neutral supplier to independent eye doctors who do not want to buy from a manufacturer that also owns competing retail stores. Meanwhile direct-to-consumer disruptors (1-800 Contacts, Warby Parker, Hubble) and Amazon keep pulling volume around the traditional professional channel. Private-equity ownership is pervasive across the independent tier.

9. Risks

• Margin compression as manufacturers sell direct and DTC channels expand — the core structural risk to a middleman.
• Vertical-integration squeeze from EssilorLuxottica and other integrated players who can bypass or undercut independent distributors.
• Supplier concentration. A few manufacturers control lens and contact-lens supply, giving them pricing and allocation power over distributors.
• E-commerce disintermediation (Amazon, online lens sellers) around the professional channel.
• Regulatory shifts in the Contact Lens Rule (verification/robocall practices have been contentious) and in vision-plan reimbursement.
• Import/tariff exposure on frames and finished goods.
• Cyclicality in the premium layer — designer frames and coating upgrades soften in downturns even as the medical core holds.
• Technology disruption — smart eyewear (e.g., camera/AI glasses) shifts value toward tech-integrated products controlled by large manufacturers, not neutral distributors.
• Labor constraints. Optometrist shortages can constrain exam capacity, creating downstream pressure on prescription orders — National Vision reported this dynamic in 2025, alongside wage pressure.[25]

10. How to invest and the outlook

Public-market routes. Because no pure-play wholesaler is listed, exposure runs through the integrated manufacturer-distributors: EssilorLuxottica (Euronext: EL; OTC ADR: ESLOY) is the broadest single proxy for the lens-and-frame supply chain; Alcon (ALC), The Cooper Companies (COO), and Bausch + Lomb (BLCO) give contact-lens and eye-care exposure; Johnson & Johnson (JNJ) and Hoya (7741) offer diversified exposure with eyewear as a slice; Safilo (SFL) provides frame-focused exposure with licensing and fashion risk. For the retail end of the same demand chain, National Vision (EYE) and Warby Parker (WRBY). Note that most of the direct manufacturer names are foreign-domiciled, so U.S. investors often access them via ADRs.[20][21][22]

Private-market routes. The purest ophthalmic-distribution assets are private and typically change hands through private equity: ABB Optical Group (New Mountain Capital), 1-800 Contacts (KKR), and VSP/Marchon.[15][17][18] Direct participation usually means PE fund exposure, secondary purchases, or acquiring/operating a regional distributor or lab. Roll-ups of independent labs and distributors remain an active PE thesis. Attractive targets have recurring practitioner relationships, diversified supplier authorization, high fill rates, automated prescription workflow, and strong inventory discipline. The principal diligence traps are customer and supplier concentration, rebates that inflate reported margin, obsolete frames, understated laboratory capital expenditure, prescription-remake rates, affiliated managed-care steering, and earnings that depend on owner sales relationships.

Near-term drivers and outlook. The demand backdrop is favorable and durable: an aging population, a genuine myopia epidemic, the mix shift to daily-disposable lenses, and premiumization support mid-single-digit market growth — the broader U.S. eyewear market is projected to grow around 4.6% annually through the early 2030s.[6] The counterweight, and the reason this is a judgment call rather than a sure thing, is channel economics: vertical integration and DTC selling keep pressure on the independent distributor's spread. The likely path is continued consolidation, with independent distributors defending margin by leaning into lab services, software, data, and neutral-supplier positioning rather than product markup alone. Smart eyewear is a wildcard — plausibly a large new demand pool, but one whose value may accrue to the integrated manufacturers rather than to the wholesale middle.

---

Sources

1. U.S. Census Bureau, County Business Patterns, 2023 (NAICS 423460) — establishments, employment, annual payroll. https://www.census.gov/programs-surveys/cbp.html
2. U.S. Census Bureau, 2022 Economic Census — Concentration/Selected Statistics (NAICS 423460) — receipts, firms, CR4/CR8/CR20/CR50, HHI. https://www.census.gov/programs-surveys/economic-census.html
3. U.S. Small Business Administration, Table of Small Business Size Standards (2023). https://www.sba.gov/document/support-table-size-standards
4. NAICS Association / U.S. Census Bureau, NAICS 423460 — Ophthalmic Goods Merchant Wholesalers (definition), 2022. https://www.naics.com/naics-code-description/?code=423460
5. IBISWorld, Glasses & Contacts Wholesaling in the US, 2025/2026. https://www.ibisworld.com/united-states/industry/glasses-contacts-wholesaling/931/
6. MarketDataForecast, U.S. Eyewear Market Size, Share & Growth, 2025. https://www.marketdataforecast.com/market-reports/united-states-eyewear-market
7. GlobeNewswire, U.S. Contact Lenses Market Size and Share Analysis 2025–2033, 2025. https://www.globenewswire.com/news-release/2025/03/10/3039922/28124/en/U-S-Contact-Lenses-Market-Size-and-Share-Analysis-2025-2033.html
8. Federal Trade Commission, The Contact Lens Rule: A Guide for Prescribers and Sellers. https://www.ftc.gov/business-guidance/resources/contact-lens-rule-guide-prescribers-sellers
9. Federal Trade Commission, Fairness to Contact Lens Consumers Act. https://www.ftc.gov/legal-library/browse/statutes/fairness-contact-lens-consumers-act
10. Electronic Code of Federal Regulations, 16 CFR Part 315 — Contact Lens Rule. https://www.ecfr.gov/current/title-16/chapter-I/subchapter-C/part-315
11. Federal Trade Commission, Statement Concerning the Proposed Acquisition of Luxottica Group by Essilor, 2018. https://www.ftc.gov/news-events/news/press-releases/2018/03/statement-federal-trade-commission-concerning-proposed-acquisition-luxottica-group-essilor
12. Pillsbury Winthrop Shaw Pittman, FTC Unconditionally Clears Luxottica's Combination with Essilor, 2018. https://www.pillsburylaw.com/en/news-and-insights/ftc-unconditionally-clears-luxottica-s-combination-with-essilor.html
13. CNBC, EssilorLuxottica gains EU okay for $8.5 billion acquisition of GrandVision, 2021. https://www.cnbc.com/2021/03/23/essilorluxottica-gains-eu-okay-for-8point5-billion-acquisition-of-grandvision.html
14. VisionMonday, EssilorLuxottica to Acquire Walman, the Largest Independent Lab Group in the U.S., 2021–2022. https://www.visionmonday.com/business/suppliers/article/essilorluxottica-to-acquire-walman-the-largest-independent-lab-group-in-the-us/
15. New Mountain Capital, ABB Optical Group (portfolio profile). https://www.newmountaincapital.com/portfolio/abb-optical-group/
16. Women In Optometry, ABB Optical Group Celebrates Its 35th Anniversary of Supporting ECPs, 2024. https://www.womeninoptometry.com/abb-optical-group/article/abb-optical-group-celebrates-its-35th-anniversary-of-supporting-ecps/
17. Digital Commerce 360, Investment firm KKR buys 1-800 Contacts for more than $3 billion, 2020. https://www.digitalcommerce360.com/2020/09/24/investment-firm-kkr-buys-1-800-contacts-for-more-than-3-billion/
18. VisionMonday, VSP Vision Acquires Professional Eye Care Associates of America (PECAA), 2022. https://www.visionmonday.com/business/article/vsp-vision-acquires-professional-eye-care-associates-of-america-pecaa
19. Wikipedia, Vision Source (EssilorLuxottica ownership since 2015). https://en.wikipedia.org/wiki/Vision_Source
20. Swissquote, Your eyes only: 8 companies to watch (EssilorLuxottica 2024 revenue; Cooper Companies revenue and segments), 2024. https://www.swissquote.com/en-lu/private/inspire/swissquote-magazine/your-eyes-only/8-companies-watch
21. Alcon, Alcon Reports Full-Year 2024 Results, 2025. https://investor.alcon.com/news-and-events/press-releases/news-details/2025/Alcon-Reports-Full-Year-2024-Results/default.aspx
22. TradingView, EssilorLuxottica SA Unsponsored ADR — OTC: ESLOY. https://www.tradingview.com/symbols/OTC-ESLOY/
23. Washington Consumers' Checkbook, How EssilorLuxottica Dominates the Eyewear Market. https://www.checkbook.org/washington-area/opticians-optometrists-buying-eyewear/articles/How-EssilorLuxottica-Dominates-the-Eyewear-Market-4568
24. The Vision Council, Market inSights 2025. https://thevisioncouncil.org/blog/us-optical-industry-reaches-695-billion-despite-declines-product-volume-and-eye-exams
25. National Vision Holdings, Inc., Form 10-K (Fiscal Year Ended January 3, 2026). https://www.sec.gov/Archives/edgar/data/1710155/000162828026014379/eye-20260103.htm
26. U.S. Census Bureau, 2022 Economic Census — Gross Margin Profile (NAICS 423460, EC2242GRMARGPROF). https://data.census.gov/table/ECNGRMARGPROF2022.EC2242GRMARGPROF
27. EssilorLuxottica, 2025 Results Press Release. https://www.essilorluxottica.com/cap/content/283060/
28. EssilorLuxottica, 2025 Annual Report. https://www.essilorluxottica.com/api/getCapContent/?download=false&id=291036
29. The Cooper Companies, Inc., Form 10-K (Fiscal Year Ended October 31, 2025). https://www.sec.gov/Archives/edgar/data/711404/000162828025055615/coo-20251031.htm
30. Bausch + Lomb Corporation, Form 10-K (Fiscal Year Ended December 31, 2025). https://www.sec.gov/Archives/edgar/data/1860742/000186074226000007/blco-20251231.htm
31. HOYA Corporation, Integrated Report 2025. https://www.hoya.com/ir/2025/en/common/files/online_report2025.pdf
32. Safilo Group, Investor Overview. https://www.safilo.com/en/investors/glance
33. Marchon Eyewear, Company Profile. https://marchon.com/
34. VSP Vision / Marcolin, VSP Vision Completes Marcolin Acquisition (Press Release, December 2025). https://www.marcolin.com/wp-content/uploads/2025/12/VSP-Vision-completes-Marcolin-Acquisition_Press-Release-December_ENG.pdf
35. National Eye Institute, Visual Impairment, Blindness Cases in U.S. Expected to Double by 2050. https://www.nei.nih.gov/about/news-and-events/news/visual-impairment-blindness-cases-us-expected-double-2050
36. U.S. Bureau of Labor Statistics, Occupational Outlook Handbook: Optometrists. https://www.bls.gov/ooh/healthcare/optometrists.htm
37. The Vision Council, Consumer inSights Q4 2024. https://thevisioncouncil.org/product/consumer-insights-q4-2024-report
38. U.S. Food & Drug Administration, Contact Lens Buying Guide. https://www.fda.gov/medical-devices/contact-lenses/buying-contact-lenses
39. U.S. Food & Drug Administration, Sunglasses, Spectacle Frames, Spectacle Lens, and Magnifying Spectacles. https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/sunglasses-spectacle-frames-spectacle-lens-and-magnifying-spectacles
40. Federal Trade Commission, FTC Announces Final Eyeglass Rule, 2024. https://www.ftc.gov/news-events/news/press-releases/2024/06/ftc-announces-final-eyeglass-rule-implementing-updates-promote-competition-expand-consumer-choice
41. The Vision Council, New Reciprocal Tariffs and Their Impact on the Optical Industry, 2025. https://thevisioncouncil.org/blog/vision-council-addresses-new-reciprocal-tariffs-and-their-impact-on-the-optical-industry